Global Ovarian Cancer Diagnostics And Therapeutics Market Report and Forecast 2024-2032

Global Ovarian Cancer Diagnostics and Therapeutics Market Report and Forecast 2024-2032


Market Outlook

According to the report by Expert Market Research (EMR), the global ovarian cancer diagnostics and therapeutics market is projected to grow at a CAGR of 9.7% between 2024 and 2032. Aided by the advancements in diagnostic technologies, the rise in ovarian cancer incidences, and the ongoing development of targeted therapeutics, the market is expected to grow significantly by 2032.

Ovarian cancer stands as one of the most lethal gynaecologic malignancies and is often termed the "silent killer" due to its late diagnosis. The pressing need for early and precise detection is driving innovations in the diagnostic sector. Techniques such as CA125 blood tests, transvaginal ultrasounds, and CT scans have been traditional diagnostic tools. Yet, emerging technologies, like liquid biopsies and genetic testing, are offering renewed hope for early detection.

Therapeutically, ovarian cancer has historically been treated with surgery followed by chemotherapy. However, the therapeutic landscape is evolving rapidly. The introduction of targeted therapies, such as PARP inhibitors and angiogenesis inhibitors, has transformed patient outcomes, especially for those with specific genetic mutations like BRCA1 and BRCA2.

Driving the global ovarian cancer diagnostics and therapeutics market growth is the rising prevalence of ovarian cancer, accentuated by factors such as aging populations, genetic predispositions, and certain lifestyle aspects. As awareness grows, screening measures are becoming more prevalent, resulting in a higher diagnostic rate and, subsequently, an increased demand for advanced therapeutics.

Moreover, the global emphasis on personalised medicine is significantly influencing the ovarian cancer therapeutics segment. With the recognition that ovarian cancer is not a single disease but a collection of subtypes, each with its molecular fingerprint, targeted therapies are gaining prominence. These drugs, tailored to individual genetic profiles, promise higher efficacy and fewer side effects compared to traditional chemotherapy.

Parallelly, the diagnostics sector is witnessing a paradigm shift which is further influencing the ovarian cancer diagnostics and therapeutics market outlook. The focus is now on non-invasive or minimally invasive techniques that can detect cancer at its nascent stages. Research is intensively underway for biomarkers that can be identified in blood or other body fluids, providing a quick and pain-free diagnostic alternative.

The industry sees a burgeoning interest in partnerships between pharma giants and biotech startups. These collaborations are primarily focused on research and development of novel diagnostic tools and therapeutics. Furthermore, with the potential of AI and machine learning in drug discovery and diagnostics, tech-pharma collaborations are on the horizon which are expected to intensify the ovarian cancer diagnostics and therapeutics market demand in the forecast period.

Market Segmentation

The market can be divided based on cancer type, modality, and region.

Market Breakup by Cancer Type
  • Epithelial Ovarian Tumors
  • Ovarian Germ Cell Tumors
  • Others
Market Breakup by Modality
  • Diagnosis
Biopsy

Blood Tests

Ultrasound

PET

CT Scan

Others
  • Therapeutics
Chemotherapy

Radiation Therapy

Immunotherapy

Hormonal Therapy

Others

Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the global ovarian cancer diagnostics and therapeutics market. Some of the major players explored in the report by Expert Market Research are as follows:
  • AstraZeneca plc
  • C.H. Boehringer Sohn AG & Ko. KG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Others
About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analysis provides the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.

Don't miss the opportunity to elevate your business intelligence and strengthen your strategic planning. Secure your organisation's future success by acquiring one of our Expert Market Research reports today.

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Ovarian Cancer Diagnostics and Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Ovarian Cancer Diagnostics and Therapeutics Historical Market (2018-2023)
8.3 Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast (2024-2032)
8.4 Global Ovarian Cancer Diagnostics and Therapeutics Market by Cancer Type
8.4.1 Epithelial Ovarian Tumors
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Ovarian Germ Cell Tumors
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Others
8.5 Global Ovarian Cancer Diagnostics and Therapeutics Market by Modality
8.5.1 Diagnosis
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.1.3 Breakup by Type
8.5.1.3.1 Biopsy
8.5.1.3.1.1 Historical Trend (2018-2023)
8.5.1.3.1.2 Forecast Trend (2024-2032)
8.5.1.3.2 Blood Tests
8.5.1.3.2.1 Historical Trend (2018-2023)
8.5.1.3.2.2 Forecast Trend (2024-2032)
8.5.1.3.3 Ultrasound
8.5.1.3.3.1 Historical Trend (2018-2023)
8.5.1.3.3.2 Forecast Trend (2024-2032)
8.5.1.3.4 PET
8.5.1.3.4.1 Historical Trend (2018-2023)
8.5.1.3.4.2 Forecast Trend (2024-2032)
8.5.1.3.5 CT Scan
8.5.1.3.5.1 Historical Trend (2018-2023)
8.5.1.3.5.2 Forecast Trend (2024-2032)
8.5.1.3.6 Others
8.5.2 Therapeutics
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.2.3 Breakup by Type
8.5.2.3.1 Chemotherapy
8.5.2.3.1.1 Historical Trend (2018-2023)
8.5.2.3.1.2 Forecast Trend (2024-2032)
8.5.2.3.2 Radiation Therapy
8.5.2.3.2.1 Historical Trend (2018-2023)
8.5.2.3.2.2 Forecast Trend (2024-2032)
8.5.2.3.3 Immunotherapy
8.5.2.3.3.1 Historical Trend (2018-2023)
8.5.2.3.3.2 Forecast Trend (2024-2032)
8.5.2.3.4 Hormonal Therapy
8.5.2.3.4.1 Historical Trend (2018-2023)
8.5.2.3.4.2 Forecast Trend (2024-2032)
8.5.2.3.5 Others
8.6 Global Ovarian Cancer Diagnostics and Therapeutics Market by Region
8.6.1 North America
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Europe
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Asia Pacific
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.6.4 Latin America
8.6.4.1 Historical Trend (2018-2023)
8.6.4.2 Forecast Trend (2024-2032)
8.6.5 Middle East and Africa
8.6.5.1 Historical Trend (2018-2023)
8.6.5.2 Forecast Trend (2024-2032)
9 North America Ovarian Cancer Diagnostics and Therapeutics Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Ovarian Cancer Diagnostics and Therapeutics Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.2 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Ovarian Cancer Diagnostics and Therapeutics Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 AstraZeneca plc
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 C.H. Boehringer Sohn AG & Ko. KG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Bristol Myers Squibb Company
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Eli Lilly and Company
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 F. Hoffmann-La Roche AG
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Ovarian Cancer Diagnostics and Therapeutics Market: Key Industry Highlights, 2018 and 2032
2. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Cancer Type (USD Million), 2018-2023
3. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Cancer Type (USD Million), 2024-2032
4. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Modality (USD Million), 2018-2023
5. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Modality (USD Million), 2024-2032
6. Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2023
7. Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Region (USD Million), 2024-2032
8. North America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
9. North America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Europe Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
11. Europe Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
13. Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Latin America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
15. Latin America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
17. Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Global Ovarian Cancer Diagnostics and Therapeutics Market Structure

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings